Recruiting

Testing a new immune therapy combined with chemotherapy before cervical cancer surgery

Plain-English translation of NCT06878222 on ClinicalTrials.gov ↗ · Source last updated April 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called iparomlimab and tuvonralimab combined with two standard chemotherapy drugs (paclitaxel and cisplatin) as a treatment given before surgery for cervical cancer. The medication works by helping your immune system recognize and attack cancer cells more effectively. Researchers hope this combination will shrink tumors and improve outcomes before surgery.

Similar immune-boosting treatments have shown promise in cervical cancer, with some patients experiencing significant tumor shrinkage before surgery. This trial is testing whether this newer medication—which works on two different parts of the immune system at once—might be even more effective and help more patients.

Do you qualify?

You likely qualify if…

you have been diagnosed with cervical cancer confirmed by a biopsy (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma)
you have locally advanced cervical cancer (stages IB3, IIA2, IIB, or IIICr with a tumor at least 4 cm) OR earlier-stage cervical cancer (IB2, IB3, IIA1, or IIA2 with a tumor up to 6 cm) if you want to preserve fertility
you are between 18–75 years old (or 18–45 if enrolling in the fertility-preservation group)
you are in good enough health to tolerate chemotherapy and surgery (ECOG score 0–1)
you have never received immune therapy before
you are willing to use contraception during the study and for 6 months after, and you have a negative pregnancy test

You likely don't qualify if…

you have a severe allergic reaction to cisplatin, paclitaxel, or the new medication
you have an active autoimmune disease requiring ongoing treatment
you are currently taking immunosuppressive drugs or high-dose steroids
you have a history of HIV, active hepatitis B or C, or active tuberculosis
you have participated in another clinical trial within the past 4 weeks

What participation looks like

If you enroll, you will receive the new immune medication combined with chemotherapy drugs as infusions before your planned cervical cancer surgery. The medication is given every 3 weeks at a dose of 5 mg/kg. You will have regular clinic visits and blood tests to monitor your health and how well the treatment is working. After completing the medication course, you will proceed to surgery as planned. The study involves close follow-up to track how you respond and any side effects you experience.

AI-generated summary from trial data · Jun 16, 2026 · Not medical advice

Trial locations(1 site)

China

The Obstetrics & Gynecology Hospital of Fudan University, Shanghai

Key details

Phase

Testing effectiveness

Sponsor

Obstetrics & Gynecology Hospital of Fudan University

Enrollment target

~35 participants

Started

March 2025

Primary completion

March 2028

Age range

18 Years – 75 Years

Sex

Female only

Last updated on clinicaltrials.gov in April 2025.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Junjun Qiu

Gynecology and obstetrics hospital of fudan university

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov